WDR5 0103WD repeat-containing protein 5 (WDR5) antagonist CAS# 890190-22-4 |
- 3-Deazaneplanocin,DZNep
Catalog No.:BCC1129
CAS No.:102052-95-9
- EPZ005687
Catalog No.:BCC2219
CAS No.:1396772-26-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 890190-22-4 | SDF | Download SDF |
PubChem ID | 6457069 | Appearance | Powder |
Formula | C21H25N3O4 | M.Wt | 383.44 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 40 mg/mL (104.32 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | methyl 3-[(3-methoxybenzoyl)amino]-4-(4-methylpiperazin-1-yl)benzoate | ||
SMILES | CN1CCN(CC1)C2=C(C=C(C=C2)C(=O)OC)NC(=O)C3=CC(=CC=C3)OC | ||
Standard InChIKey | ZPLBXOVTSNRBFB-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C21H25N3O4/c1-23-9-11-24(12-10-23)19-8-7-16(21(26)28-3)14-18(19)22-20(25)15-5-4-6-17(13-15)27-2/h4-8,13-14H,9-12H2,1-3H3,(H,22,25) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | WD repeat-containing protein 5 (WDR5) antagonist (Kd = 450 nM). Disrupts WDR5 interaction with MLL and inhibits MLL core complex methyltransferase activity in vitro. Has no effect on a panel of seven other methyltransferases, including SETD7. |
WDR5 0103 Dilution Calculator
WDR5 0103 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.608 mL | 13.0398 mL | 26.0797 mL | 52.1594 mL | 65.1992 mL |
5 mM | 0.5216 mL | 2.608 mL | 5.2159 mL | 10.4319 mL | 13.0398 mL |
10 mM | 0.2608 mL | 1.304 mL | 2.608 mL | 5.2159 mL | 6.5199 mL |
50 mM | 0.0522 mL | 0.2608 mL | 0.5216 mL | 1.0432 mL | 1.304 mL |
100 mM | 0.0261 mL | 0.1304 mL | 0.2608 mL | 0.5216 mL | 0.652 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Nutlin-3
Catalog No.:BCC2254
CAS No.:890090-75-2
- LUF6000
Catalog No.:BCC1710
CAS No.:890087-21-5
- 2'-Deoxyinosine
Catalog No.:BCN8544
CAS No.:890-38-0
- 2,4-Dihydroxyacetophenone
Catalog No.:BCN4441
CAS No.:89-84-9
- Thymol
Catalog No.:BCN3794
CAS No.:89-83-8
- Pulegone
Catalog No.:BCN3856
CAS No.:89-82-7
- (+)-Menthone
Catalog No.:BCC9239
CAS No.:89-80-5
- Neoisomenthol
Catalog No.:BCC8169
CAS No.:20752-34-5
- Mesalamine
Catalog No.:BCC4798
CAS No.:89-57-6
- Edaravone
Catalog No.:BCC2480
CAS No.:89-25-8
- Quinolinic acid
Catalog No.:BCC6573
CAS No.:89-00-9
- Dipsanoside B
Catalog No.:BCN2878
CAS No.:889678-64-2
- Dregeoside A11
Catalog No.:BCN3993
CAS No.:89020-11-1
- erythro-Guaiacylglycerol beta-coniferyl ether
Catalog No.:BCN1315
CAS No.:890317-92-7
- VU 29
Catalog No.:BCC7936
CAS No.:890764-36-0
- VU 1545
Catalog No.:BCC7649
CAS No.:890764-63-3
- ML 349
Catalog No.:BCC5612
CAS No.:890819-86-0
- GSK 650394
Catalog No.:BCC4070
CAS No.:890842-28-1
- 24,25-Epoxytirucall-7-en-3,23-dione
Catalog No.:BCN4437
CAS No.:890928-81-1
- BAMB-4
Catalog No.:BCC5428
CAS No.:891025-25-5
- 4-O-Demethylisokadsurenin D
Catalog No.:BCN6650
CAS No.:89104-59-6
- Odoratisol A
Catalog No.:BCN7813
CAS No.:891182-93-7
- Betulin caffeate
Catalog No.:BCN4438
CAS No.:89130-86-9
- MK-8776 (SCH-900776)
Catalog No.:BCC3817
CAS No.:891494-63-6
Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5.[Pubmed:22989411]
Biochem J. 2013 Jan 1;449(1):151-9.
WDR5 (WD40 repeat protein 5) is an essential component of the human trithorax-like family of SET1 [Su(var)3-9 enhancer-of-zeste trithorax 1] methyltransferase complexes that carry out trimethylation of histone 3 Lys4 (H3K4me3), play key roles in development and are abnormally expressed in many cancers. In the present study, we show that the interaction between WDR5 and peptides from the catalytic domain of MLL (mixed-lineage leukaemia protein) (KMT2) can be antagonized with a small molecule. Structural and biophysical analysis show that this antagonist binds in the WDR5 peptide-binding pocket with a Kd of 450 nM and inhibits the catalytic activity of the MLL core complex in vitro. The degree of inhibition was enhanced at lower protein concentrations consistent with a role for WDR5 in directly stabilizing the MLL multiprotein complex. Our data demonstrate inhibition of an important protein-protein interaction and form the basis for further development of inhibitors of WDR5-dependent enzymes implicated in MLL-rearranged leukaemias or other cancers.